Anti-HMGCR Antibody Picoband® 0,00647 Vervoeging

HMG-CoA reductase is the rate-limiting enzyme for cholesterol synthesis and is regulated via a negative feedback mechanism mediated by sterols and non-sterol metabolites derived from mevalonate, the product of the reaction catalyzed by reductase. Normally in mammalian cells this enzyme is suppressed by cholesterol derived from the internalization and degradation of low density lipoprotein (LDL) via the LDL receptor. Competitive inhibitors of the reductase induce the expression of LDL receptors in the liver, which in turn increases the catabolism of plasma LDL and lowers the plasma concentration of cholesterol, an important determinant of atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Major vault protein; MVP; Lung resistance-related protein; MVP; LRP

HMGCR

3156

P04035

Human

No cross-reactivity with other proteins.

E.coli-derived human HMGCR recombinant protein (Position: H268-V842) .

Present in most normal tissues. Higher expression observed in epithelial cells with secretory and excretory functions, as well as in cells chronically exposed to xenobiotics, such as bronchial cells and cells lining the intestine. Overexpressed in many multidrug-resistant cancer cells.

Flow Cytometry

Cancer, Nuclear Import/Export, Protein Trafficking, Signal Transduction

Immunogen affinity purified.

Liquid

Required for normal vault structure. Vaults are multi- subunit structures that may act as scaffolds for proteins involved in signal transduction. Vaults may also play a role in nucleo- cytoplasmic transport. Down-regulates IFNG-mediated STAT1 signaling and subsequent activation of JAK. Down-regulates SRC activity and signaling through MAP kinases.

1. Aulchenko, Y. S., Ripatti, S., Lindqvist, I., Boomsma, D., Heid, I. M., Pramstaller, P. P., Penninx, B. W. J. H., Janssens, A. C. J. W., Wilson, W. F., Spector, T., Martin, N. G., Pedersen, N. L. {and 45 others}: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nature Genet. 41: 47-55, 2009. 2. Chasman, D. I., Posada, D., Subrahmanyan, L., Cook, N. R., Stanton, V. P., Jr., Ridker, P. M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291: 2821-2827, 2004. 3. Goldstein, J. L., Brown, M. S. Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.

At -20 ̊C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

6

Major vault protein

Cytoplasm.

Rabbit IgG

Each vial contains 50% glycerol, 0.9% NaCl, 0.2% Na2HPO4, 0.02% NaN3.